Immune modulation by melanoma-derived factors

Experimental Dermatology

Volumn 17, Issue 12, 2008, Pages 977-985

  Ilkovitch, Dan ^a   Lopez, Diana M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Chemokines; Cytokines; Immunosuppression immunotherapy; Melanoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

CANCER RISK; CELL COMMUNICATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; MACROPHAGE; MELANOMA; NEUTROPHIL; NONHUMAN; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SUPPRESSOR CELL; TUMOR IMMUNITY;

ANIMALS; CHEMOKINE CCL2; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; INTERLEUKINS; MELANOMA; MODELS, IMMUNOLOGICAL; TRANSFORMING GROWTH FACTOR BETA;

EID: 56349142086     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00779.x     Document Type: Review

References (135)

1. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006: 313: 1960-1964.
2. Morgan R A, Dudley M E, Wunderlich J R et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006: 314: 126-129.
3. Dudley M E, Wunderlich J R, Yang J C et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005: 23: 2346-2357.
4. Rosenberg S A, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986: 233: 1318-1321.
5. Dudley M E, Wunderlich J R, Robbins P F et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002: 298: 850-854.
6. McCarter M D, Baumgartner J, Escobar G A et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 2007: 14: 2854-2860.
7. Turk M J, Guevara-Patino J A, Rizzuto G A, Engelhorn M E, Sakaguchi S, Houghton A N. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004: 200: 771-782.
8. North R J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982: 155: 1063-1074.
9. Kuwana M, Kaburaki J, Wright T M, Kawakami Y, Ikeda Y. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001: 31: 2547-2557.
10. Mahnke K, Qian Y, Knop J, Enk A H. Induction of CD4+/CD25+regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003: 101: 4862-4869.
11. Akbari O, DeKruyff R H, Umetsu D T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001: 2: 725-731.
12. Asseman C, Mauze S, Leach M W, Coffman R L, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999: 190: 995-1004.
13. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001: 194: 629-644.
14. Cederbom L, Hall H, Ivars F. CD4+CD25+regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 2000: 30: 1538-1543.
15. Ermann J, Szanya V, Ford G S, Paragas V, Fathman C G, Lejon K. CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. J Immunol 2001: 167: 4271-4275.
16. Nagai H, Horikawa T, Hara I et al. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 2004: 13: 613-620.
17. Mahnke K, Schonfeld K, Fondel S et al. Depletion of CD4+ CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007: 120: 2723-2733.
18. Filipazzi P, Valenti R, Huber V et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007: 25: 2546-2553.
19. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006: 16: 53-65.
20. Bunt S K, Yang L, Sinha P, Clements V K, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007: 67: 10019-10026.
21. Movahedi K, Guilliams M, Van den Bossche J et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood 2008: 111: 4233-4244.
22. Rodriguez P C, Hernandez C P, Quiceno D et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005: 202: 931-939.
23. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005: 5: 641-654.
24. Liu C, Yu S, Kappes J et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007: 109: 4336-4342.
25. Sinha P, Clements V K, Bunt S K, Albelda S M, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007: 179: 977-983.
26. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002: 23: 549-555.
27. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992: 176: 1693-1702.
28. Nathan C F. Respiratory burst in adherent human neutrophils: Triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 1989: 73: 301-306.
29. Warren T L, Weiner G J. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 2000: 7: 168-173.
30. Cebon J S, Lieschke G J. Granulocyte-macrophage colony-stimulating factor for cancer treatment. Oncology 1994: 51: 177-188.
31. Vuylsteke R J, Molenkamp B G, Van Leeuwen P A et al. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res 2006: 12: 2826-2833.
32. Vuylsteke R J, Molenkamp B G, Gietema H A et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 2004: 64: 8456-8460.
33. Clark D A, Chaouat G, Mogil R, Wegmann T G. Prevention of spontaneous abortion in DBA/2-mated CBA/J mice by GM-CSF involves CD8+ T cell-dependent suppression of natural effector cell cytotoxicity against trophoblast target cells. Cell Immunol 1994: 154: 143-152.
34. Pradeep C R, Kuttan G. Piperine is a potent inhibitor of nuclear factor-kappaB (NF-kappaB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells. Int Immunopharmacol 2004: 4: 1795-1803.
35. Ciotti P, Rainero M L, Nicolo G et al. Cytokine expression in human primary and metastatic melanoma cells: Analysis in fresh bioptic specimens. Melanoma Res 1995: 5: 41-47.
36. Singh R K, Gutman M, Radinsky R. Heterogeneity of cytokine and growth factor gene expression in human melanoma cells with different metastatic potentials. J Interferon Cytokine Res 1995: 15: 81-87.
37. Bennicelli J L, Guerry D IV. Production of multiple cytokines by cultured human melanomas. Exp Dermatol 1993: 2: 186-190.
38. Hensley C, Spitzler S, McAlpine B E et al. In vivo human melanoma cytokine production: Inverse correlation of GM-CSF production with tumor depth. Exp Dermatol 1998: 7: 335-341.
39. Ciotti P, Pesce G P, Cafiero F et al. Intercellular adhesion molecule-1 (ICAM-1) and granulocyte-macrophage colony stimulating factor (GM-CSF) co-expression in cutaneous malignant melanoma lesions. Melanoma Res 1999: 9: 253-260.
40. Charyulu V I, Lopez D M. Elevated GM-CSF levels in tumor bearing mice upregulate IL-6 production by B cells via a mechanism independent of TNF-alpha. Int J Oncol 2000: 16: 161-167.
41. Sabatini M, Chavez J, Mundy G R, Bonewald L F. Stimulation of tumor necrosis factor release from monocytic cells by the A375 human melanoma via granulocyte-macrophage colony-stimulating factor. Cancer Res 1990: 50: 2673-2678.
42. Fu Y X, Cai J P, Chin Y H, Watson G A, Lopez D M. Regulation of leukocyte binding to endothelial tissues by tumor-derived GM-CSF. Int J Cancer 1992: 50: 585-588.
43. Sotomayor E M, Fu Y X, Lopez-Cepero M et al. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol 1991: 147: 2816-2823.
44. Fu Y X, Watson G A, Kasahara M, Lopez D M. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J Immunol 1991: 146: 783-789.
45. Fu Y X, Watson G, Jimenez J J, Wang Y, Lopez D M. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 1990: 50: 227-234.
46. Watson G A, Fu Y X, Lopez D M. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J Leukoc Biol 1991: 49: 126-138.
47. Bronte V, Chappell D B, Apolloni E et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999: 162: 5728-5737.
48. Xie Y, Fernandez M E, Streilein J W, Lopez D M. Epidermal Langerhans cells from mice bearing a granulocyte macrophage-colony stimulating factor-producing mammary tumor display impaired accessory functions. Anticancer Res 1996: 16: 9-16.
49. Vasu C, Dogan R N, Holterman M J, Prabhakar B S. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol 2003: 170: 5511-5522.
50. Serafini P, Carbley R, Noonan K A, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004: 64: 6337-6343.
51. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo M P, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007: 18: 226-232.
52. Allavena P, Bianchi G, Zhou D et al. Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol 1994: 24: 3233-3236.
53. Carr M W, Roth S J, Luther E, Rose S S, Springer T A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994: 91: 3652-3656.
54. Kuna P, Reddigari S R, Rucinski D, Oppenheim J J, Kaplan A P. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med 1992: 175: 489-493.
55. Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 1999: 10: 61-86.
56. Huang S, Singh R K, Xie K et al. Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 1994: 39: 231-238.
57. Zhang T, Somasundaram R, Berencsi K et al. Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol 2006: 36: 457-467.
58. Lamagna C, Aurrand-Lions M, Imhof B A. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006: 80: 705-713.
59. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006: 42: 717-727.
60. Nesbit M, Schaider H, Miller T H, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001: 166: 6483-6490.
61. Graves D T, Barnhill R, Galanopoulos T, Antoniades H N. Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am J Pathol 1992: 140: 9-14.
62. Gazzaniga S, Bravo A I, Guglielmotti A et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007: 127: 2031-2041.
63. Torisu H, Ono M, Kiryu H et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. Int J Cancer 2000: 85: 182-188.
64. Owen J L, Lopez D M, Grosso J F et al. The expression of CCL2 by T lymphocytes of mammary tumor bearers: Role of tumor-derived factors. Cell Immunol 2005: 235: 122-135.
65. Zijlmans H J, Fleuren G J, Baelde H J, Eilers P H, Kenter G G, Gorter A. The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol 2006: 208: 507-517.
66. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000: 6: 3282-3289.
67. Youngs S J, Ali S A, Taub D D, Rees R C. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer 1997: 71: 257-266.
68. Brat D J, Bellail A C, Van Meir E G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 2005: 7: 122-133.
69. Koch A E, Polverini P J, Kunkel S L et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992: 258: 1798-1801.
70. Singh R K, Varney M L, Bucana C D, Johansson S L. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999: 9: 383-387.
71. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001: 19: 577-583.
72. Peng H H, Liang S, Henderson A J, Dong C. Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp Cell Res 2007: 313: 551-559.
73. Liu G, Zhang F, Lee J, Dong Z. Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1. Cytokine 2005: 31: 241-249.
74. Gebhardt C, Averbeck M, Viertel A et al. Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp Dermatol 2007: 16: 636-643.
75. Chakrabarti S, Patel K D. Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils. J Leukoc Biol 2005: 78: 279-288.
76. Melani C, Sangaletti S, Barazzetta F M, Werb Z, Colombo M P. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007: 67: 11438-11446.
77. Letterio J J, Roberts A B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998: 16: 137-161.
78. Berking C, Takemoto R, Schaider H et al. Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res 2001: 61: 8306-8316.
79. Fujimaki T, Price J E, Fan D et al. Selective growth of human melanoma cells in the brain parenchyma of nude mice. Melanoma Res 1996: 6: 363-371.
80. Krasagakis K, Garbe C, Schrier P I, Orfanos C E. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 1994: 14: 2565-2571.
81. Reed J A, McNutt N S, Prieto V G, Albino A P. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 1994: 145: 97-104.
82. Valenti R, Huber V, Filipazzi P et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006: 66: 9290-9298.
83. Huang B, Pan P Y, Li Q et al. Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006: 66: 1123-1131.
84. Zhang X, Huang H, Yuan J et al. CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J Immunol 2005: 175: 2931-2937.
85. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson J T, Whiteside T L. A unique subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007: 13: 4345-4354.
86. Esquerre M, Tauzin B, Guiraud M, Muller S, Saoudi A, Valitutti S. Human regulatory T cells inhibit polarization of T helper cells toward antigen-presenting cells via a TGF-beta-dependent mechanism. Proc Natl Acad Sci USA 2008: 105: 2550-2555.
87. Hacham M, Argov S, White R M, Segal S, Apte R N. Different patterns of interleukin-1alpha and interleukin-1 beta expression in organs of normal young and old mice. Eur Cytokine Netw 2002: 13: 55-65.
88. Coussens L M, Werb Z. Inflammation and cancer. Nature 2002: 420: 860-867.
89. Elaraj D M, Weinreich D M, Varghese S et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 2006: 12: 1088-1096.
90. Margalit O, Eisenbach L, Amariglio N et al. Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. Br J Cancer 2003: 89: 314-319.
91. Voronov E, Shouval D S, Krelin Y et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003: 100: 2645-2650.
92. Loffek S, Zigrino P, Angel P, Anwald B, Krieg T, Mauch C. High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1alpha and basic fibroblast growth factor-mediated mechanisms. J Invest Dermatol 2005: 124: 638-643.
93. Weinreich D M, Elaraj D M, Puhlmann M et al. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res 2003: 63: 5957-5961.
94. Anasagasti M J, Olaso E, Calvo F et al. Interleukin 1-dependent and -independent mouse melanoma metastases. J Natl Cancer Inst 1997: 89: 645-651.
95. Song X, Krelin Y, Dvorkin T et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol 2005: 175: 8200-8208.
96. Bunt S K, Sinha P, Clements V K, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006: 176: 284-290.
97. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit Rev Oncol Hematol 2007: 66: 1-9.
98. Yurkovetsky Z R, Kirkwood J M, Edington H D et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007: 13: 2422-2428.
99. Mouawad R, Soubrane C, Rixe O, Khayat D, Spano J P. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res 2006: 16: 335-340.
100. Soubrane C, Rixe O, Meric J B, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res 2005: 15: 199-204.
101. Lee S O, Chun J Y, Nadiminty N, Lou W, Gao A C. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007: 67: 764-773.
102. Mouawad R, Khayat D, Merle S, Antoine E C, Gil-Delgado M, Soubrane C. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res 1999: 9: 181-188.
103. Von Felbert V, Cordoba F, Weissenberger J et al. Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol 2005: 166: 831-841.
104. Kast R E. Melanoma inhibition by cyclooxygenase inhibitors: Role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. Med Oncol 2007: 24: 1-6.
105. Yu S, Liu C, Su K et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 2007: 178: 6867-6875.
106. Duluc D, Delneste Y, Tan F et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007: 110: 4319-4330.
107. Herbeuval J P, Lelievre E, Lambert C, Dy M, Genin C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol 2004: 172: 4630-4636.
108. Yue F Y, Dummer R, Geertsen R et al. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997: 71: 630-637.
109. Dummer W, Bastian B C, Ernst N, Schanzle C, Schwaaf A, Brocker E B. Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996: 66: 607-610.
110. Torisu-Itakura H, Lee J H, Huynh Y, Ye X, Essner R, Morton D L. Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother (1997) 2007: 30: 831-838.
111. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 2001: 19: 239-247.
112. Kryczek I, Zou L, Rodriguez P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006: 203: 871-881.
113. Kryczek I, Wei S, Zhu G et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007: 67: 8900-8905.
114. Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk A H. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999: 93: 1634-1642.
115. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk A H. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002: 99: 2468-2476.
116. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine M D, Kaveri S V. Cutting edge: Human CD4+ CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004: 172: 4676-4680.
117. Armstrong C A, Tara D C, Hart C E, Kock A, Luger T A, Ansel J C. Heterogeneity of cytokine production by human malignant melanoma cells. Exp Dermatol 1992: 1: 37-45.
118. Moretti S, Pinzi C, Spallanzani A et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer 1999: 84: 160-168.
119. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000: 12: 547-554.
120. Voelcker V, Gebhardt C, Averbeck M et al. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp Dermatol 2008: 17: 100-107.
121. Li Q, Withoff S, Verma I M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005: 26: 318-325.
122. Naugler W E, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008: 18: 19-26.
123. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007: 7: 41-51.
124. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004: 10: 48-54.
125. Wang W, Edington H D, Rao U N et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007: 13: 1523-1531.
126. Ilkovitch D, Handel-Fernandez M E, Herbert L M, Lopez D M. Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells. Cancer Res 2008: 68: 2427-2435.
127. Loberg R D, Ying C, Craig M et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007: 67: 9417-9424.
128. Wang F L, Qin W J, Wen W H et al. TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer. Cancer Immunol Immunother 2007: 56: 1785-1793.
129. Toomey D, Conroy H, Jarnicki A G, Higgins S C, Sutton C, Mills K H. Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. Vaccine 2008: 26: 3540-3549.
130. Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol 2007: 19: 121-127.
131. Parmiani G, Castelli C, Rivoltini L et al. Immunotherapy of melanoma. Semin Cancer Biol 2003: 13: 391-400.
132. Asadullah K, Sterry W, Trefzer U. Cytokine therapy in dermatology. Exp Dermatol 2002: 11: 97-106.
133. Bosch J J, Thompson J A, Srivastava M K et al. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 2007: 67: 4499-4506.
134. Cheung M C, Perez E A, Molina M A et al. Defining the role of surgery for primary gastrointestinal tract melanoma. J Gastrointest Surg 2007: 12: 731-738.
135. Amersi F F, Terando A M, Goto Y et al. Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res 2008: 14: 638-645.